About Us
We has been working together for over 10 years to elucidate basic mechanisms of lung cells and tissues. We have co-invented methodologies and our record of accomplishment is exemplified by multiple co-authored, peer-reviewed publications. Mechanobiologix is an early-stage company in the field of 3D models for preclinical drug screening, having been found in 2019. Since then, it has secured a Phase I STTR for the development of MechanoWell®, and an “Ignition Award” from Boston University to refine and simplify MechanoWell® with the ultimate goal to further its commercialization potential.
Jae Hun Kim, Ph. D.
Co-founder and Interim CEO. Dr. Kim is an expert in experimental and computational methods in soft tissue and cell mechanics, materials science, mechanical design and device fabrication.
Bela Suki, Ph. D.
Co-founder: Dr. Suki is a Professor in the Department of Biomedical Engineering at Boston University. He is a world authority on lung mechanics, IPF, COPD, and mechanotransduction, with a primary focus on the role of mechanical forces on lung extracellular matrix function.
Ramaswamy Krishnan, Ph. D.
Co-founder: Dr. Krishnan is an Associate Professor in Emergency Medicine at Harvard Medical School. He is an academic scientist and entrepreneur with a successful record of turning laboratory-based biomechanical methods into commercial assays for drug screening and validation. He is also an expert of asthma biomechanics.